Logo

OpiCalc

FavoritesSpecialtiesDrugsGuidelinesMost Used

All Specialties

OpiCalc Logo
FavoritesSpecialtiesDrugsGuidelinesMost Used
FavesSpecsDrugsGuidesTop
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
OpiCalc Logo

OpiCalc

Easy, fast, and private medical tools for clinicians. Always free.

No Login Required
Ready for the Bedside

Resources

About UsEditorial PolicyMedical DisclaimerPrivacy PolicyTerms of UseCookie Policy

Support

Contact Us

Clinical Notice:OpiCalc is not a substitute for professional clinical judgment. Always verify dosages and guidelines.

OpiCalc © 2018-2026

•

All Rights Reserved

Registry Hub
Peer-Reviewed Evidence
HomeDrug RegistryCompareCYPROHEPTADINE vs HYDROXYZINE
Comparative Pharmacology

CYPROHEPTADINE vs HYDROXYZINE Comparison

Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.

Clinical EssentialsPharmacokineticsSpecial PopulationsSafety & MonitoringPregnancy & LactationClinical Insights
Differential Analysis

CYPROHEPTADINE vs HYDROXYZINE

Head-to-head clinical comparison of therapeutic indices and safety profiles.

View HYDROXYZINE Monograph
CYPROHEPTADINE
Pharmacology
Pending
HYDROXYZINE
Antihistamine
Category A/B

Clinical Essentials

CYPROHEPTADINE
HYDROXYZINE
Mechanism of Action
CYPROHEPTADINE
Data Pending
HYDROXYZINE

Hydroxyzine is a first-generation antihistamine that acts as a competitive antagonist at histamine H1 receptors in the gastrointestinal tract, blood vessels, and respiratory tract. It also exhibits sedative, anxiolytic, and antiemetic properties, possibly through central nervous system depression and anticholinergic effects.

Indications
CYPROHEPTADINE
Data Pending
HYDROXYZINE

Pruritus due to allergic conditions such as urticaria, atopic dermatitis, and contact dermatitis,Anxiety and tension (as a short-term management in adults),Preoperative sedation and to reduce anxiety prior to surgery,Nausea and vomiting (off-label),Insomnia (off-label)

Standard Dosing
CYPROHEPTADINE
Data Pending
HYDROXYZINE

25-100 mg orally 3-4 times daily; 50-100 mg IM every 4-6 hours as needed. Maximum oral dose: 600 mg/day in divided doses.

Direct Interaction
CYPROHEPTADINE
MODERATE Risk
HYDROXYZINE
MODERATE Risk

Pharmacokinetics

CYPROHEPTADINE
HYDROXYZINE
Half-Life
CYPROHEPTADINE
Data Pending
HYDROXYZINE

Terminal elimination half-life: 14-25 hours (mean ~20 h). In elderly or hepatic impairment, may be prolonged; antihistamine effect persists beyond half-life due to active metabolite.

Metabolism

Special Populations

CYPROHEPTADINE
HYDROXYZINE
Renal Adjustments
CYPROHEPTADINE
Data Pending
HYDROXYZINE

GFR 10-50 m L/min: administer every 12 hours. GFR <10 m L/min: administer every 24 hours. Not recommended for use in patients with severe renal impairment (e GFR <30 m L/min/1.73 m²) due to increased risk of neurotoxicity.

Hepatic Adjustments

Safety & Monitoring

CYPROHEPTADINE
HYDROXYZINE
Black Box Warnings
CYPROHEPTADINE
No Black Box Warning
HYDROXYZINE

Pregnancy & Lactation

CYPROHEPTADINE
HYDROXYZINE
Teratogenic Risk
CYPROHEPTADINE
Data Pending
HYDROXYZINE

Hydroxyzine is generally considered low risk for teratogenicity. Animal studies have shown no consistent evidence of fetal harm. Human data are limited but do not indicate a significant increase in major malformations. In the first trimester, use only if clearly needed. In the second and third trimesters, there is a potential risk of neonatal respiratory depression, hypotonia, and withdrawal symptoms if used near term or in high doses. Avoid use during labor and delivery due to potential maternal hypotension and fetal effects.

Clinical Insights

CYPROHEPTADINE
HYDROXYZINE
Clinical Pearls
CYPROHEPTADINE
Data Pending
HYDROXYZINE

Hydroxyzine is a first-generation antihistamine with anxiolytic, sedative, and antiemetic properties. It is commonly used for pruritus, anxiety, and premedication. Avoid concurrent use with CNS depressants due to additive sedation. In elderly patients, risk of confusion and falls is increased; consider alternative therapies. Hydroxyzine has anticholinergic effects; use cautiously in patients with glaucoma, urinary retention, or prostatic hyperplasia. Note that hydroxyzine can cause QT prolongation at high doses or in combination with other QT-prolonging drugs.

Safety Verification

Known Interactions

CYPROHEPTADINE Risks3
Cyproheptadine + Metyrosine
moderate

"Cyproheptadine may increase the sedative activities of Metyrosine."

Cyproheptadine + Droperidol
moderate

"Cyproheptadine may increase the central nervous system depressant (CNS depressant) activities of Droperidol."

Cyproheptadine + Magnesium sulfate
moderate

"Cyproheptadine may increase the central nervous system depressant (CNS depressant) activities of Magnesium sulfate."

HYDROXYZINE Risks3
Hydroxyzine + Dronabinol
moderate

"Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Dronabinol."

Hydroxyzine + Metyrosine
moderate

"Hydroxyzine may increase the sedative activities of Metyrosine."

Hydroxyzine + Droperidol
Clinical Q&A

Frequently Asked Questions

1. What is the primary difference between CYPROHEPTADINE and HYDROXYZINE?

CYPROHEPTADINE and HYDROXYZINE are distinct pharmacological agents. CYPROHEPTADINE belongs to the indicated class and is primarily used for specified clinical guidelines. HYDROXYZINE belongs to the Antihistamine class and is primarily used for Pruritus due to allergic conditions such as urticaria, atopic dermatitis, and contact dermatitisAnxiety and tension (as a short-term management in adults)Preoperative sedation and to reduce anxiety prior to surgeryNausea and vomiting (off-label)Insomnia (off-label). Their specific mechanisms of action, pharmacokinetic characteristics, and side effects differ.

2. Are CYPROHEPTADINE and HYDROXYZINE safe during pregnancy?

The maternal-fetal safety profiles of these drugs differ. CYPROHEPTADINE carries a safety status of Pending, whereas HYDROXYZINE safety is classified as Category A/B. Consult a board-certified physician or healthcare specialist to establish an accurate, individualized pregnancy risk assessment before starting either therapy.

CYPROHEPTADINE
Data Pending
HYDROXYZINE

Hydroxyzine is primarily metabolized by the liver via CYP3A4 and CYP2D6 isoenzymes. The major active metabolite is cetirizine, which is also a histamine H1 receptor antagonist.

Excretion
CYPROHEPTADINE
Data Pending
HYDROXYZINE

Renal: approximately 70% as metabolites, less than 1% unchanged. Fecal/biliary: minor. Cetirizine (active metabolite) also renally eliminated.

Protein Binding
CYPROHEPTADINE
Data Pending
HYDROXYZINE

93% bound to plasma proteins, primarily albumin.

VD (L/kg)
CYPROHEPTADINE
Data Pending
HYDROXYZINE

16 L/kg (range 7-20 L/kg), indicating extensive tissue distribution; higher Vd suggests large extravascular binding.

Bioavailability
CYPROHEPTADINE
Data Pending
HYDROXYZINE

Oral: approximately 80%; IM: >80% (almost complete and rapid); IV: 100%.

CYPROHEPTADINE
Data Pending
HYDROXYZINE

Child-Pugh Class B: reduce dose by 50% and/or increase dosing interval to every 12-24 hours. Child-Pugh Class C: use with caution; consider alternative agent or reduce dose by 75% and administer every 24 hours.

Pediatric Dosing
CYPROHEPTADINE
Data Pending
HYDROXYZINE

Oral: 2 mg/kg/day in divided doses every 6-8 hours. Maximum: 50 mg/day for children <6 years; 100 mg/day for 6-12 years. IM: 0.5-1 mg/kg every 6-8 hours, not to exceed 50 mg per dose.

Geriatric Dosing
CYPROHEPTADINE
Data Pending
HYDROXYZINE

Initiate at lowest dose (25 mg orally 3-4 times daily) and titrate cautiously due to increased risk of sedation, confusion, and anticholinergic effects. Maximum recommended dose: 100 mg/day in divided doses.

FDA Black Box Warning

There is no FDA black box warning for hydroxyzine.

Warnings/Precautions
CYPROHEPTADINE
Data Pending
HYDROXYZINE
  • May cause sedation and impair ability to drive or operate machinery.
  • May cause QT prolongation, especially in patients with risk factors such as electrolyte imbalance, bradycardia, or concurrent use of other QT-prolonging drugs.
  • Use with caution in patients with hepatic impairment, as metabolism may be reduced.
  • Anticholinergic effects: may exacerbate conditions such as glaucoma, urinary retention, hyperthyroidism, or asthma.
  • May increase the risk of seizures in susceptible patients.
Contraindications
CYPROHEPTADINE
Data Pending
HYDROXYZINE
  • Hypersensitivity to hydroxyzine or any of its components.
  • Early pregnancy (first trimester) due to potential teratogenic effects; use in later pregnancy only if clearly needed.
  • Breastfeeding: caution advised as hydroxyzine is excreted in breast milk.
  • Concomitant use of other CNS depressants may potentiate sedation.
  • Avoid in patients with known QT prolongation or history of arrhythmias.
Adverse Reactions
CYPROHEPTADINE
Data Pending
HYDROXYZINE
Data Pending
Food Interactions
CYPROHEPTADINE
Data Pending
HYDROXYZINE

Hydroxyzine may be taken with or without food. Grapefruit juice may increase hydroxyzine serum concentrations and risk of adverse effects; avoid concurrent consumption. High-fat meals can delay but not significantly reduce absorption. No other food restrictions are required.

Lactation Summary
CYPROHEPTADINE
Data Pending
HYDROXYZINE

Hydroxyzine is excreted into breast milk in small amounts. The milk-to-plasma ratio is estimated at approximately 0.5. In infants, it may cause sedation, irritability, or poor feeding. Because of the potential for serious adverse reactions in nursing infants, consider the developmental and health benefits of breastfeeding along with the mother’s clinical need for hydroxyzine and any potential adverse effects on the breastfed infant. Alternatives with better safety profiles may be preferred.

Pregnancy Dosing
CYPROHEPTADINE
Data Pending
HYDROXYZINE

Pharmacokinetic changes in pregnancy (increased volume of distribution, reduced plasma albumin, and altered hepatic metabolism) may affect hydroxyzine concentrations. However, specific dose adjustments for pregnancy are not well-established. Clinical monitoring for efficacy and adverse effects is recommended, and using the lowest effective dose for the shortest duration is prudent. No routine dose adjustment is mandated, but individual patient response should guide therapy.

Maternal Safety Status
CYPROHEPTADINE
Pending
HYDROXYZINE
Category A/B
Patient Counseling
CYPROHEPTADINE
Data Pending
HYDROXYZINE

Take hydroxyzine exactly as prescribed and do not exceed the recommended dose.,Avoid driving or operating heavy machinery until you know how hydroxyzine affects you, as it may cause drowsiness or dizziness.,Avoid alcohol and other central nervous system depressants (e.g., benzodiazepines, opioids) while taking hydroxyzine.,Notify your doctor if you experience blurred vision, dry mouth, difficulty urinating, or rapid heartbeat.,Do not stop taking hydroxyzine abruptly if using for anxiety; consult your doctor for a taper plan.,Store at room temperature, away from moisture and heat.

moderate

"Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Droperidol."